

Development of a therapeutic agent for ulcerative colitis by regulating glycogen metabolism of immune cells and intestinal epithelial cells

Innovo Therapeutics, Inc.



IMMUNOLOGY	Phase 1
Product Type	Small molecules
Indication	Ulcerative Colitis
Target	Not opened
MoA(Mechanism of Action)	<p>Inhibition of glycogen metabolism by INV-101 leads to</p> <ul style="list-style-type: none"> - significantly attenuate proliferation of immune cells - decrease pro-inflammatory cytokine production in serum - significantly suppress ROS (Reactive oxygen species) resulting in tissue injury
Competitiveness	<p>Competitive Efficacy</p> <ul style="list-style-type: none"> - New small molecule with novel mechanism of action - Anti inflammatory effects by modulating glycogen metabolism of immune cells & ROS scavenging - Potential competitive efficacy compared to pan-Jak inhibitor Superior Safety - Proven safe target in diabetes - No pan-immunosuppression - Broad safety margin in animal model
Development Stage	Phase I
Route of Administration	Oral